What does CUSIP 92790C104 represent in this 13F holders report?

CUSIP 92790C104 is the security identifier for VRDN - Viridian Therapeutics, Inc.\DE - Common Stock used to aggregate holder disclosures.

How many institutions held VRDN - Viridian Therapeutics, Inc.\DE - Common Stock in Q2 2023?

127 institutional investors reported VRDN - Viridian Therapeutics, Inc.\DE - Common Stock for Q2 2023. Use the holders table for investor-level position and value details.

Viridian Therapeutics, Inc.\DE - Common Stock (VRDN)

CUSIP: 92790C104

Q2 2023 13F Holders as of 30 Jun 2023

Type / Class: Equity / Common Stock
Shares outstanding: 95,489,675
Total 13F shares: 47,119,787
Share change: +4,050,978
Total reported value: $1,121,040,780
Put/Call ratio: 93%
Price per share: $23.79
Number of holders: 127
Value change: +$92,340,222
Number of buys: 86
Number of sells: 49

Quarterly Holders Quick Answers

What is CUSIP 92790C104?
CUSIP 92790C104 identifies VRDN - Viridian Therapeutics, Inc.\DE - Common Stock in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Next holder-history checks

These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.

Back to full security ownership history for the broader multi-quarter picture.
Latest 13F filings for newly reported positions across managers.
Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
SEC investors directory for manager drilldown.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Newer quarter: Q3 2023
Previous quarter: Q1 2023

Recent filing periods for CUSIP 92790C104:

Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024

Top shareholders of VRDN - Viridian Therapeutics, Inc.\DE - Common Stock (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
BlackRock Finance, Inc.	13F	Company	2.9%	2,773,386	$70,554,941	—	31 Mar 2023	13F
VR Adviser, LLC	13F	Company	2.8%	2,699,865	$68,684,566	—	31 Mar 2023	13F
STATE STREET CORP	13F	Company	2.5%	2,401,812	$61,102,097	—	31 Mar 2023	13F
Commodore Capital LP	13F	Company	2.3%	2,189,659	$55,704,925	—	31 Mar 2023	13F
VANGUARD GROUP INC	13F	Company	2.2%	2,130,233	$54,193,128	—	31 Mar 2023	13F
Paradigm Biocapital Advisors LP	13F	Company	2.2%	2,085,698	$53,060,157	—	31 Mar 2023	13F
RA CAPITAL MANAGEMENT, L.P.	13F	Company	2.1%	2,007,946	$51,082,146	—	31 Mar 2023	13F
PERCEPTIVE ADVISORS LLC	13F	Company	1.8%	1,736,386	$44,173,660	—	31 Mar 2023	13F
Vivo Capital, LLC	13F	Company	1.8%	1,678,207	$42,693,586	—	31 Mar 2023	13F
Fairmount Funds Management LLC	13F	Company	1.4%	1,369,623	$34,843,209	—	31 Mar 2023	13F
ALLIANCEBERNSTEIN L.P.	13F	Company	1.3%	1,244,150	$31,651,176	—	31 Mar 2023	13F
Frazier Life Sciences Public Fund, L.P.	3/4/5	10%+ Owner	— class O/S missing	1,505,200	$31,609,200	—	23 Sep 2021	3/4/5
Deep Track Capital, LP	13F	Company	1.3%	1,230,259	$31,297,789	—	31 Mar 2023	13F
Yiheng Capital Management, L.P.	13F	Company	1.3%	1,228,534	$31,253,905	—	31 Mar 2023	13F
Octagon Capital Advisors LP	13F	Company	1.2%	1,185,000	$30,146,400	—	31 Mar 2023	13F
PICTET ASSET MANAGEMENT SA	13F	Company	1.1%	1,042,965	$26,533,030	—	31 Mar 2023	13F
Logos Global Management LP	13F	Company	0.99%	950,000	$24,168,000	—	31 Mar 2023	13F
Cormorant Asset Management, LP	13F	Company	0.89%	850,000	$21,624,000	—	31 Mar 2023	13F
GEODE CAPITAL MANAGEMENT, LLC	13F	Company	0.81%	776,112	$19,744,298	—	31 Mar 2023	13F
TANG CAPITAL MANAGEMENT LLC	13F	Company	0.73%	692,925	$17,628,012	—	31 Mar 2023	13F
TCG Crossover Management, LLC	13F	Company	0.69%	663,610	$16,882,238	—	31 Mar 2023	13F
MARSHALL WACE, LLP	13F	Company	0.66%	629,320	$16,009,901	—	31 Mar 2023	13F
MILLENNIUM MANAGEMENT LLC	13F	Company	0.64%	614,089	$15,622,000	—	31 Mar 2023	13F
Nuveen Asset Management, LLC	13F	Company	0.6%	577,627	$14,695,000	—	31 Mar 2023	13F
Hood River Capital Management LLC	13F	Company	0.59%	566,498	$14,412,000	—	31 Mar 2023	13F
Polar Capital Holdings Plc	13F	Company	0.58%	550,000	$13,992,000	—	31 Mar 2023	13F
Kynam Capital Management, LP	13F	Company	0.57%	543,603	$13,829,260	—	31 Mar 2023	13F
Artal Group S.A.	13F	Company	0.53%	504,978	$12,847,000	—	31 Mar 2023	13F
EAGLE ASSET MANAGEMENT INC	13F	Company	0.48%	461,665	$11,744,000	—	31 Mar 2023	13F
MORGAN STANLEY	13F	Company	0.45%	433,134	$11,018,928	—	31 Mar 2023	13F
DRIEHAUS CAPITAL MANAGEMENT LLC	13F	Company	0.43%	406,777	$10,348,407	—	31 Mar 2023	13F
Jonathan Violin	3/4/5	Chief Executive Officer, Director	— mixed-class rows	720,110 mixed-class rows	$10,099,005	—	02 Feb 2023	3/4/5
NORTHERN TRUST CORP	13F	Company	0.39%	370,926	$9,436,356	—	31 Mar 2023	13F
GOLDMAN SACHS GROUP INC	13F	Company	0.37%	354,910	$9,028,910	—	31 Mar 2023	13F
FRED ALGER MANAGEMENT, LLC	13F	Company	0.34%	323,676	$8,234,317	—	31 Mar 2023	13F
5AM Venture Management, LLC	13F	Company	0.29%	280,000	$7,123,200	—	31 Mar 2023	13F
BANK OF AMERICA CORP /DE/	13F	Company	0.27%	254,821	$6,482,647	—	31 Mar 2023	13F
DEUTSCHE BANK AG\	13F	Company	0.27%	254,114	$6,464,660	—	31 Mar 2023	13F
Scott Dunseth Myers	3/4/5	Chief Executive Officer, Director	— class O/S missing	259,500	$5,449,500	—	12 Apr 2023	3/4/5
Atlas Venture Advisors, Inc.	13F	Company	0.22%	209,505	$5,329,807	—	31 Mar 2023	13F
NORGES BANK	13F	Company	0.22%	208,800	$5,311,872	—	31 Mar 2023	13F
Rafferty Asset Management, LLC	13F	Company	0.19%	176,926	$4,500,997	—	31 Mar 2023	13F
Ghost Tree Capital, LLC	13F	Company	0.18%	175,000	$4,452,000	—	31 Mar 2023	13F
CITIGROUP INC	13F	Company	0.18%	168,101	$4,276,489	—	31 Mar 2023	13F
ACUTA CAPITAL PARTNERS, LLC	13F	Company	0.18%	168,000	$4,273,920	—	31 Mar 2023	13F
BVF INC/IL	13F	Company	0.18%	168,000	$4,273,920	—	31 Mar 2023	13F
FMR LLC	13F	Company	0.15%	144,148	$3,667,126	—	31 Mar 2023	13F
Bank of New York Mellon Corp	13F	Company	0.15%	139,635	$3,552,314	—	31 Mar 2023	13F
Connor, Clark & Lunn Investment Management Ltd.	13F	Company	0.14%	136,265	$3,466,582	—	31 Mar 2023	13F
Kopp Family Office, LLC	13F	Company	0.14%	131,288	$3,340,000	—	31 Mar 2023	13F

Institutional Holders of Viridian Therapeutics, Inc.\DE - Common Stock (VRDN) as of Q2 2023

As of 30 Jun 2023, Viridian Therapeutics, Inc.\DE - Common Stock (VRDN) was held by 127 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 47,119,787 shares. The largest 10 holders included BlackRock Inc., VR Adviser, LLC, STATE STREET CORP, VANGUARD GROUP INC, Paradigm Biocapital Advisors LP, COMMODORE CAPITAL LP, RA CAPITAL MANAGEMENT, L.P., PERCEPTIVE ADVISORS LLC, Vivo Capital, LLC, and Polar Capital Holdings Plc. This page lists 127 institutional shareholders reporting positions in this security for the Q2 2023 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q2 2023 vs Q1 2023 Across Filers

Q1 2023 holders

134

Q2 2023 holders

127

Holder diff

-7

Investor	Q1 2023 Shares	Q2 2023 Shares	Share Diff	Share Chg %	Q1 2023 Value $	Q2 2023 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.